Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zurich, Switzerland (S.A.H.); Waggoner Center for Alcohol and Addiction Research, University of Texas at Austin, Austin, Texas (R.J.H., C.M.B., M.A.C., U.S.L., R.A.H.); Science for Life Laboratory, KTH Royal Institute of Technology and Stockholm University, Stockholm, Sweden (T.B., E.L.); and Department of Biochemistry and Biophysics, Center for Biomembrane Research, Science for Life Laboratory, Stockholm University, Stockholm, Sweden (J.C.).
Mol Pharmacol. 2013 Nov;84(5):670-8. doi: 10.1124/mol.113.087692. Epub 2013 Aug 15.
GABA(A) receptors play a crucial role in the actions of general anesthetics. The recently published crystal structure of the general anesthetic propofol bound to Gloeobacter violaceus ligand-gated ion channel (GLIC), a bacterial homolog of GABA(A) receptors, provided an opportunity to explore structure-based ligand discovery for pentameric ligand-gated ion channels (pLGICs). We used molecular docking of 153,000 commercially available compounds to identify molecules that interact with the propofol binding site in GLIC. In total, 29 compounds were selected for functional testing on recombinant GLIC, and 16 of these compounds modulated GLIC function. Active compounds were also tested on recombinant GABA(A) receptors, and point mutations around the presumed binding pocket were introduced into GLIC and GABA(A) receptors to test for binding specificity. The potency of active compounds was only weakly correlated with properties such as lipophilicity or molecular weight. One compound was found to mimic the actions of propofol on GLIC and GABA(A), and to be sensitive to mutations that reduce the action of propofol in both receptors. Mutant receptors also provided insight about the position of the binding sites and the relevance of the receptor's conformation for anesthetic actions. Overall, the findings support the feasibility of the use of virtual screening to discover allosteric modulators of pLGICs, and suggest that GLIC is a valid model system to identify novel GABA(A) receptor ligands.
GABA(A) 受体在全身麻醉剂的作用中发挥着关键作用。最近发表的通用麻醉剂异丙酚与 Gloeobacter violaceus 配体门控离子通道(GLIC)结合的晶体结构,GLIC 是 GABA(A) 受体的细菌同源物,为探索基于结构的五聚体配体门控离子通道(pLGICs)配体发现提供了机会。我们使用 153,000 种商业上可获得的化合物的分子对接来鉴定与 GLIC 中异丙酚结合位点相互作用的分子。总共选择了 29 种化合物在重组 GLIC 上进行功能测试,其中 16 种化合物调节 GLIC 功能。活性化合物也在重组 GABA(A) 受体上进行了测试,并在 GLIC 和 GABA(A) 受体中引入了假定结合口袋周围的点突变,以测试结合特异性。活性化合物的效力与亲脂性或分子量等特性仅弱相关。发现一种化合物模拟异丙酚对 GLIC 和 GABA(A) 的作用,并且对降低两种受体中异丙酚作用的突变敏感。突变受体还为结合位点的位置和受体构象对麻醉作用的相关性提供了见解。总体而言,这些发现支持使用虚拟筛选发现 pLGICs 的变构调节剂的可行性,并表明 GLIC 是识别新型 GABA(A) 受体配体的有效模型系统。